RxDoctor Payments Data

Eben Eno Mbei, MD

Cardiovascular Disease · Milwaukee, WINPI 1740698554

Payments from drug & device makers

$1,260in general payments, 2019–2025

Across 23 payments — averaging $54.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$309
  • Abiomed$141
  • E.r. Squibb & Sons, L.L.C.$141
  • Boehringer Ingelheim$125
  • Boston Scientific$112
  • Amgen$107
  • plus $326 from 5 others

What the payments were for

  • Food & beverage$1,260100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,260 in reported general payments places this provider in the 50th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$195,848
Medicare patients
1,150
Services billed
2,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$102,904
XareltoRivaroxaban47$51,134
EntrestoSacubitril/Valsartan29$32,967
Ranolazine ErRanolazine15$2,712
Metoprolol Succinate180$2,118
Bumetanide41$1,760
Atorvastatin Calcium135$1,472
Rosuvastatin Calcium126$1,288
Prasugrel Hcl13$980
Carvedilol96$900
Chlorthalidone44$887
Ezetimibe30$796
Potassium Chloride26$708
Diltiazem 24hr ErDiltiazem Hcl18$647
Losartan Potassium83$647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$102,90484 claims
Johnson & JohnsonXarelto$91$51,13447 claims
NovartisEntresto$28$32,96729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →